TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05832515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate for Injection
Description: Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
Study: NCT02765113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Facial nerve combing
Description: Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Facial and Trigeminal nerve combing
Description: Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression.
Study: NCT02881931

Intervention type: BEHAVIORAL
Intervention: FuRST 2.0
Description: Cognitive Pre-testing of new Functional Rating Scale

Intervention type: BEHAVIORAL
Intervention: FuRST 2.0
Description: Cognitive Pre-testing of new Functional Rating Scale

Intervention type: BEHAVIORAL
Intervention: FuRST 2.0
Description: Cognitive Pre-testing of new Functional Rating Scale
Study: NCT01707654

Intervention type: DEVICE
Group type: OTHER
Intervention: Nerve flap
Description: Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
Study: NCT04293926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.
Study: NCT02164357

Intervention type: PROCEDURE
Intervention: EVT (endovascular treatment )

Intervention type: PROCEDURE
Intervention: EVT (endovascular treatment )

Intervention type: PROCEDURE
Intervention: IVT (intravenous thrombolytic therapy)

Intervention type: PROCEDURE
Intervention: IVT (intravenous thrombolytic therapy)
Study: NCT00480558

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7
Study: NCT02431910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional elastic tape
Description: application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
Study: NCT06801886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarine supplementation
Description: 900 mg of silymarin supplementation daily during the early post-transplant period, (for 30 days) under standard treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Placebo supplementation during the early post-transplant period (30 days) under standard treatment
Study: NCT00738959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328
Description: Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
Study: NCT02739100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Study: NCT01505153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pbi-shRNA STMN1 LP
Description: This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
Study: NCT05473806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 Mg Oral Tablet
Description: 24weeks dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: 24weeks dose
Study: NCT00787709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways
Description: 3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
Study: NCT00937287

Intervention type: OTHER
Intervention: There is no intervention in this study.
Description: No intervention is provided in this study as it is exploratory.
Study: NCT03570749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT05169450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diterpene ginkgolides meglumine injection
Description: Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginaton
Description: Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
Study: NCT01247883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04634817
Description: single dose, 20mg, tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04634817
Description: single dose, 20mg, solution
Study: NCT01897038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
Study: NCT01329549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
Study: NCT03021889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
Study: NCT01343316

Intervention type: DEVICE
Intervention: Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)
Description: To determine the benefits of utilizing one type of transpyloric tube over another.

Intervention type: DEVICE
Intervention: Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)
Description: To determine the benefits of utilizing one type of transpyloric tube over another.

Intervention type: DEVICE
Intervention: Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)
Description: To determine the benefits of utilizing one type of transpyloric tube over another.
Study: NCT02431910

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo Functional elastic tape
Description: application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
Study: NCT06174454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Pediatric Physiotherapy
Description: Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
Study: NCT01611688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0215-0384
Description: I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0215-0384
Description: The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
Study: NCT01176084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low carbohydrate diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low carbohydrate diet and exercise
Study: NCT03570749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT06801964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: OTHER
Intervention: Stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and Fish Oil
Description: milk/carbohydrate mixture and supplementation of 3.5g of EPA+DHA (7g of fish oil)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and Fish Oil
Description: milk/carbohydrate mixture and supplementation of 3.5g of EPA+DHA (7g of fish oil)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and Olive Oil
Description: milk/carbohydrate mixture with olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and Olive Oil
Description: milk/carbohydrate mixture with olive oil
Study: NCT04326231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usability assessment of Cognoa ASD Therapeutic Device
Description: Usability assessment of Cognoa ASD Therapeutic Device
Study: NCT01529632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237
Description: NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAB149
Description: QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
Study: NCT06801964

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate and Olive Oil
Description: carbohydrate mixture with olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate and Olive Oil
Description: carbohydrate mixture with olive oil
Study: NCT06800443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silica-based fluoride toothpaste containing clay, charcoal, blue covarine and green covarine
Description: Silica-based toothpaste containing charcoal, clay, blue covarine, green covarine and fluoride as sodium fluoride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silica-based fluoride toothpaste with blue covarine
Description: Silica-based toothpaste containing lower level of blue covarine and fluoride as sodium monofluorophosphate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silica-based fluoride toothpaste with blue covarine
Description: Silica-based toothpaste containing higher level blue covarine and fluoride as sodium monofluorophosphate

Intervention type: OTHER
Group type: OTHER
Intervention: Control silica-based fluoride toothpaste
Description: Control silica-based toothpaste containing fluoride as sodium fluoride
Study: NCT01496300

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Manual Intervention
Description: Implantation of acetabular component without the use of the navigation system information

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigated Intervention
Description: Navigated implantation of acetabular component using OrthoPilot image free navigation system
Study: NCT00400595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: topical ointment (already in widespread clinical use)
Study: NCT04433091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Hydroxybenzylamine
Description: 2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given TID for seven days prior to ablation and 28 days post ablation.
Study: NCT04448561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8082
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: morphine
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT00400595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysporin Triple
Study: NCT02917070

Intervention type: OTHER
Intervention: Patients
Description: In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
Study: NCT03558061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK4290
Description: ALK4290 400 mg tablet twice a day
Study: NCT03351465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management
Description: The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living42 that directly incorporates our previously optional modules for depression into the main program. The computerized internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed.
Study: NCT03019159

Intervention type: DEVICE
Intervention: Teleconsulting
Study: NCT04680858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DECT
Description: Use of a digital enhanced telecommunication headset for team communication
Study: NCT04523935

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fructose powder identical with the drugs was used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.
Description: Drugs were used either singly or in combination guided by clinical findings and investigations.
Study: NCT00873457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
Study: NCT02043106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plantar vibration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plantar vibration
Study: NCT02539199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol, modified-release pessary
Description: Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol, per-oral tablets
Description: First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
Study: NCT02255448

Intervention type: DEVICE
Group type: OTHER
Intervention: Transthoracic echo and esCCO stroke volume
Description: All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
Study: NCT02419222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism Adaptation
Description: PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
Study: NCT03571009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: utilization of PAAS
Description: utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
Study: NCT04553744

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT01126268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin (Altabax)
Description: Retapamulin ointment, applied topically twice daily for five days
Study: NCT02762656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine drip during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine drip during surgery
Study: NCT04711447

Intervention type: DEVICE
Group type: OTHER
Intervention: kinesio-tape
Description: Twenty-two individuals with healthy shoulders completed 10 repetitions of an arm elevation task during three taping conditions (no-tape, experimental KT, sham KT) and 2 loading conditions (no-load and loaded).

Intervention type: DEVICE
Group type: OTHER
Intervention: kinesio-tape
Description: Twenty-two individuals with healthy shoulders completed 10 repetitions of an arm elevation task during three taping conditions (no-tape, experimental KT, sham KT) and 2 loading conditions (no-load and loaded).
Study: NCT02420288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
Study: NCT01608698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mcg ethinylestradiol/2 mg chlormadinone acetate
Description: By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mcg ethinylestradiol/3 mg drospirenone
Description: By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
Study: NCT01202019

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Circuit Resistance Training (CRT)
Description: CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT)
Description: CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
Study: NCT04040192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole 2%
Description: Crisaborole ointment 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle ointment
Study: NCT04840537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP
Description: endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage